Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients

Barbara Mora, Elisa Rumi, Paola Guglielmelli, Daniela Barraco, Margherita Maffioli, Alessandro Rambaldi, Marianna Caramella, Rami Komrokji, Jason Gotlib, Jean Jacques Kiladjian, Francisco Cervantes, Timothy Devos, Francesca Palandri, Valerio De Stefano, Marco Ruggeri, Richard T. Silver, Giulia Benevolo, Francesco Albano, Chiara Cavalloni, Daniela PietraTiziano Barbui, Giada Rotunno, Mario Cazzola, Alessandro Maria Vannucchi, Toni Giorgino, Francesco Passamonti

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Patients with myeloproliferative neoplasms (MPN) are known to have higher incidence of nonhematological second primary malignancies (SPM) compared to general population. In the MYSEC study on 781 secondary myelofibrosis (SMF) patients, the incidence of SPM after SMF diagnosis resulted 0.98/100 patient-years. When including non-melanoma skin cancers (NMSC), the incidence arose to 1.56/100 patientyears. In SMF, JAK inhibitor treatment was associated only with NMSC occurrence. Then, we merged the MYSEC cohort with a large dataset of PV and ET not evolving into SMF. In this subanalysis, we did not find any correlation between SPM and SMF occurrence. These findings highlight the need of studies aimed at identifying MPN patients at higher risk of SPM.

Original languageEnglish
Pages (from-to)4089-4092
Number of pages4
JournalCancer Medicine
Volume8
Issue number9
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Thrombocytosis
Primary Myelofibrosis
Second Primary Neoplasms
Skin Neoplasms
Incidence
Neoplasms
Population

Keywords

  • JAK inhibitors
  • Second malignancy
  • Secondary myelofibrosis

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis : A study on 2233 patients. / Mora, Barbara; Rumi, Elisa; Guglielmelli, Paola; Barraco, Daniela; Maffioli, Margherita; Rambaldi, Alessandro; Caramella, Marianna; Komrokji, Rami; Gotlib, Jason; Kiladjian, Jean Jacques; Cervantes, Francisco; Devos, Timothy; Palandri, Francesca; Stefano, Valerio De; Ruggeri, Marco; Silver, Richard T.; Benevolo, Giulia; Albano, Francesco; Cavalloni, Chiara; Pietra, Daniela; Barbui, Tiziano; Rotunno, Giada; Cazzola, Mario; Vannucchi, Alessandro Maria; Giorgino, Toni; Passamonti, Francesco.

In: Cancer Medicine, Vol. 8, No. 9, 01.01.2019, p. 4089-4092.

Research output: Contribution to journalArticle

Mora, B, Rumi, E, Guglielmelli, P, Barraco, D, Maffioli, M, Rambaldi, A, Caramella, M, Komrokji, R, Gotlib, J, Kiladjian, JJ, Cervantes, F, Devos, T, Palandri, F, Stefano, VD, Ruggeri, M, Silver, RT, Benevolo, G, Albano, F, Cavalloni, C, Pietra, D, Barbui, T, Rotunno, G, Cazzola, M, Vannucchi, AM, Giorgino, T & Passamonti, F 2019, 'Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients', Cancer Medicine, vol. 8, no. 9, pp. 4089-4092. https://doi.org/10.1002/cam4.2107
Mora, Barbara ; Rumi, Elisa ; Guglielmelli, Paola ; Barraco, Daniela ; Maffioli, Margherita ; Rambaldi, Alessandro ; Caramella, Marianna ; Komrokji, Rami ; Gotlib, Jason ; Kiladjian, Jean Jacques ; Cervantes, Francisco ; Devos, Timothy ; Palandri, Francesca ; Stefano, Valerio De ; Ruggeri, Marco ; Silver, Richard T. ; Benevolo, Giulia ; Albano, Francesco ; Cavalloni, Chiara ; Pietra, Daniela ; Barbui, Tiziano ; Rotunno, Giada ; Cazzola, Mario ; Vannucchi, Alessandro Maria ; Giorgino, Toni ; Passamonti, Francesco. / Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis : A study on 2233 patients. In: Cancer Medicine. 2019 ; Vol. 8, No. 9. pp. 4089-4092.
@article{00a5676e6964456f8956c62cbdf036a9,
title = "Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients",
abstract = "Patients with myeloproliferative neoplasms (MPN) are known to have higher incidence of nonhematological second primary malignancies (SPM) compared to general population. In the MYSEC study on 781 secondary myelofibrosis (SMF) patients, the incidence of SPM after SMF diagnosis resulted 0.98/100 patient-years. When including non-melanoma skin cancers (NMSC), the incidence arose to 1.56/100 patientyears. In SMF, JAK inhibitor treatment was associated only with NMSC occurrence. Then, we merged the MYSEC cohort with a large dataset of PV and ET not evolving into SMF. In this subanalysis, we did not find any correlation between SPM and SMF occurrence. These findings highlight the need of studies aimed at identifying MPN patients at higher risk of SPM.",
keywords = "JAK inhibitors, Second malignancy, Secondary myelofibrosis",
author = "Barbara Mora and Elisa Rumi and Paola Guglielmelli and Daniela Barraco and Margherita Maffioli and Alessandro Rambaldi and Marianna Caramella and Rami Komrokji and Jason Gotlib and Kiladjian, {Jean Jacques} and Francisco Cervantes and Timothy Devos and Francesca Palandri and Stefano, {Valerio De} and Marco Ruggeri and Silver, {Richard T.} and Giulia Benevolo and Francesco Albano and Chiara Cavalloni and Daniela Pietra and Tiziano Barbui and Giada Rotunno and Mario Cazzola and Vannucchi, {Alessandro Maria} and Toni Giorgino and Francesco Passamonti",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/cam4.2107",
language = "English",
volume = "8",
pages = "4089--4092",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",
number = "9",

}

TY - JOUR

T1 - Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis

T2 - A study on 2233 patients

AU - Mora, Barbara

AU - Rumi, Elisa

AU - Guglielmelli, Paola

AU - Barraco, Daniela

AU - Maffioli, Margherita

AU - Rambaldi, Alessandro

AU - Caramella, Marianna

AU - Komrokji, Rami

AU - Gotlib, Jason

AU - Kiladjian, Jean Jacques

AU - Cervantes, Francisco

AU - Devos, Timothy

AU - Palandri, Francesca

AU - Stefano, Valerio De

AU - Ruggeri, Marco

AU - Silver, Richard T.

AU - Benevolo, Giulia

AU - Albano, Francesco

AU - Cavalloni, Chiara

AU - Pietra, Daniela

AU - Barbui, Tiziano

AU - Rotunno, Giada

AU - Cazzola, Mario

AU - Vannucchi, Alessandro Maria

AU - Giorgino, Toni

AU - Passamonti, Francesco

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Patients with myeloproliferative neoplasms (MPN) are known to have higher incidence of nonhematological second primary malignancies (SPM) compared to general population. In the MYSEC study on 781 secondary myelofibrosis (SMF) patients, the incidence of SPM after SMF diagnosis resulted 0.98/100 patient-years. When including non-melanoma skin cancers (NMSC), the incidence arose to 1.56/100 patientyears. In SMF, JAK inhibitor treatment was associated only with NMSC occurrence. Then, we merged the MYSEC cohort with a large dataset of PV and ET not evolving into SMF. In this subanalysis, we did not find any correlation between SPM and SMF occurrence. These findings highlight the need of studies aimed at identifying MPN patients at higher risk of SPM.

AB - Patients with myeloproliferative neoplasms (MPN) are known to have higher incidence of nonhematological second primary malignancies (SPM) compared to general population. In the MYSEC study on 781 secondary myelofibrosis (SMF) patients, the incidence of SPM after SMF diagnosis resulted 0.98/100 patient-years. When including non-melanoma skin cancers (NMSC), the incidence arose to 1.56/100 patientyears. In SMF, JAK inhibitor treatment was associated only with NMSC occurrence. Then, we merged the MYSEC cohort with a large dataset of PV and ET not evolving into SMF. In this subanalysis, we did not find any correlation between SPM and SMF occurrence. These findings highlight the need of studies aimed at identifying MPN patients at higher risk of SPM.

KW - JAK inhibitors

KW - Second malignancy

KW - Secondary myelofibrosis

UR - http://www.scopus.com/inward/record.url?scp=85070199969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070199969&partnerID=8YFLogxK

U2 - 10.1002/cam4.2107

DO - 10.1002/cam4.2107

M3 - Article

C2 - 31173472

AN - SCOPUS:85070199969

VL - 8

SP - 4089

EP - 4092

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

IS - 9

ER -